Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2006;332:550 (4 March), doi:10.1136/bmj.332.7540.550-a
| The first 150 words of the full text of this article appear below. |
EDITORBuscemi et al assert that there is no evidence base for exogenous melatonin for secondary sleep disorder.1
Lewy et al have shown that low doses of melatonin (0.5 mg) reset circadian rhythm but not high doses (2 mg).2 The prolonged half life of melatonin and the sensitivity of the circadian rhythm to its presence mean that in trying to achieve phase advancement or phase delay melatonin has a limited window of opportunity. Too low a dose and no effect, too high and the chronobiological effects are lost and only the direct somnolent action is experienced.
Until very recently there have been no commercially available preparations of the correct dose, substantially hindering research. As melatonin is of most use where there is circadian rhythm dysregulation the correct dose must be used at the right time. It would be a shame if a potentially useful treatment for a limited range
M E Jan Wise, consultant psychiatrist
London NW6 6BX jan.wise@nhs.net
Israeli students are refusing to perform intimate examinations on anaesthetised women without their informed consent.